PapersFlow Research Brief
Angiogenesis and VEGF in Cancer
Research Guide
What is Angiogenesis and VEGF in Cancer?
Angiogenesis and VEGF in cancer refers to the process by which tumors induce new blood vessel formation through vascular endothelial growth factor (VEGF) signaling to support their growth, invasion, and metastasis.
This field examines the molecular mechanisms of tumor angiogenesis, with VEGF as a central regulator that promotes endothelial cell proliferation and vessel formation in cancers. Over 74,965 papers have been published on angiogenesis and VEGF in cancer. Key studies identify VEGF receptors on endothelial cells and describe how tumors switch to an angiogenic phenotype via patterns like hypoxia-induced VEGF expression.
Topic Hierarchy
Research Sub-Topics
VEGF Signaling Pathways
This sub-topic dissects VEGF receptor activation, downstream PI3K/AKT and MAPK cascades, and crosstalk in endothelial cells. Researchers map molecular interactions regulating angiogenesis.
Tumor Angiogenesis Mechanisms
This sub-topic investigates angiogenic switch, tip/stalk cell dynamics, and pericyte-endothelial interactions in tumors. Researchers study hypoxia-driven VEGF expression and vessel maturation.
Anti-Angiogenic Therapy Resistance
This sub-topic explores adaptive resistance via alternative angiogenic factors, vessel co-option, and metastasis promotion. Researchers analyze clinical trial data and biomarkers.
Vascular Normalization Therapy
This sub-topic examines optimal anti-VEGF dosing to normalize tumor vasculature, improving perfusion and drug delivery. Researchers correlate normalization with treatment outcomes.
Endothelial Progenitor Cells in Angiogenesis
This sub-topic studies recruitment, incorporation, and paracrine roles of EPCs in tumor neovascularization. Researchers track bone marrow-derived contributions to vessel formation.
Why It Matters
Angiogenesis driven by VEGF enables tumor growth beyond 1-2 mm³ by providing oxygen and nutrients, as shown in "Tumor Angiogenesis: Therapeutic Implications" by Sherwood et al. (1971), which linked solid tumor neovascularization to vigorous capillary sprouting. Anti-angiogenic therapies targeting VEGF, such as ranibizumab, prevent vision loss in neovascular age-related macular degeneration, with patients gaining 7.2 letters of visual acuity over two years in clinical trials ("Ranibizumab for Neovascular Age-Related Macular Degeneration" by Rosenfeld et al., 2006). Microvessel density in invasive breast carcinoma predicts metastasis, with high counts (>60 per 200x field) correlating to lymph node involvement or distant spread ("Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma" by Weidner et al., 1991). Vascular normalization via anti-VEGF agents improves perfusion and drug delivery, as evidenced in preclinical models ("Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy" by Jain, 2005).
Reading Guide
Where to Start
"Tumor Angiogenesis: Therapeutic Implications" by Sherwood et al. (1971) is the starting point for beginners, as it provides the foundational observation that solid tumor growth requires neovascularization and introduces therapeutic targeting of this process, cited over 10,000 times.
Key Papers Explained
"Tumor Angiogenesis: Therapeutic Implications" by Sherwood et al. (1971) established the necessity of neovascularization for tumor growth, which Folkman expanded in "Angiogenesis in cancer, vascular, rheumatoid and other disease" (1995) to define the angiogenic switch. Ferrara et al. (2003) in "The biology of VEGF and its receptors" identified VEGF as the key mediator acting on endothelial receptors. Carmeliet and Jain (2000) in "Angiogenesis in cancer and other diseases" integrated these into broader pathology, while Asahara et al. (1997) in "Isolation of Putative Progenitor Endothelial Cells for Angiogenesis" added progenitor cell contributions. Jain (2005) in "Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy" built on this by proposing normalization over destruction for therapy.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research extends vascular normalization concepts from Jain (2005) to combination regimens, examines pericyte-endothelial interactions in resistance, and refines progenitor cell roles from Asahara et al. (1997), with over 74,965 works indicating sustained focus on signaling pathways and clinical translation.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Tumor Angiogenesis: Therapeutic Implications | 1971 | New England Journal of... | 10.1K | ✕ |
| 2 | The biology of VEGF and its receptors | 2003 | Nature Medicine | 9.5K | ✕ |
| 3 | Angiogenesis in cancer and other diseases | 2000 | Nature | 8.9K | ✕ |
| 4 | Isolation of Putative Progenitor Endothelial Cells for Angioge... | 1997 | Science | 8.7K | ✕ |
| 5 | Angiogenesis in cancer, vascular, rheumatoid and other disease | 1995 | Nature Medicine | 7.6K | ✕ |
| 6 | Patterns and Emerging Mechanisms of the Angiogenic Switch duri... | 1996 | Cell | 6.9K | ✓ |
| 7 | Ranibizumab for Neovascular Age-Related Macular Degeneration | 2006 | New England Journal of... | 5.8K | ✓ |
| 8 | Mechanisms of angiogenesis | 1997 | Nature | 5.7K | ✕ |
| 9 | Tumor Angiogenesis and Metastasis — Correlation in Invasive Br... | 1991 | New England Journal of... | 5.7K | ✕ |
| 10 | Normalization of Tumor Vasculature: An Emerging Concept in Ant... | 2005 | Science | 5.3K | ✕ |
Frequently Asked Questions
What role does VEGF play in tumor angiogenesis?
VEGF acts as the primary stimulator of endothelial cell proliferation, migration, and survival to form new tumor blood vessels. "The biology of VEGF and its receptors" by Ferrara et al. (2003) details how VEGF binds specific tyrosine kinase receptors on endothelial cells to initiate angiogenic signaling. This process supports tumor expansion by delivering nutrients and oxygen.
How do tumors induce the angiogenic switch?
Tumors activate the angiogenic switch through mechanisms like hypoxia-inducible VEGF overexpression and protease-mediated matrix remodeling. "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis" by Hanahan and Folkman (1996) identifies distinct patterns including increased angiogenic stimulators and decreased inhibitors. This switch enables progression from dormant avascular masses to invasive tumors.
What are endothelial progenitor cells in angiogenesis?
Endothelial progenitor cells, isolated from peripheral blood via CD34 and VEGF receptor-2 markers, differentiate into endothelial cells and incorporate into new vessels. "Isolation of Putative Progenitor Endothelial Cells for Angiogenesis" by Asahara et al. (1997) demonstrated their role in ischemia-induced angiogenesis in animal models. These cells contribute to tumor neovascularization by homing to hypoxic sites.
What is vascular normalization in anti-angiogenic therapy?
Vascular normalization restructures abnormal tumor vessels to improve perfusion, oxygenation, and drug delivery rather than destroying them. "Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy" by Jain (2005) shows that low-dose VEGF inhibitors transiently normalize vasculature in tumors. This enhances chemotherapy efficacy and reduces metastasis in preclinical studies.
How is tumor angiogenesis assessed clinically?
Tumor angiogenesis is quantified by microvessel density in the most vascularized areas using immunohistochemistry. "Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma" by Weidner et al. (1991) found that counts exceeding 60 microvessels per 200x field predict metastatic risk in breast cancer. This metric serves as a prognostic indicator independent of lymph node status.
Open Research Questions
- ? How can resistance to VEGF-targeted anti-angiogenic therapies be overcome in heterogeneous tumor vasculatures?
- ? What are the precise contributions of endothelial progenitor cells versus local sprouting in tumor angiogenesis?
- ? How does pericyte coverage influence the efficacy of vascular normalization strategies?
- ? Which downstream signaling pathways beyond VEGF receptors sustain angiogenesis in advanced cancers?
- ? Can biomarkers of the angiogenic switch predict response to combination anti-angiogenic and immunotherapy?
Recent Trends
The field encompasses 74,965 papers on angiogenesis and VEGF in cancer, building on classics like Folkman's works from the 1970s-1990s that defined tumor neovascularization and the angiogenic switch.
VEGF receptor biology from Ferrara et al. remains central, with Jain's 2005 normalization concept influencing ongoing therapy designs.
2003No recent preprints or news in the last 12 months were available, suggesting steady maturation rather than abrupt shifts.
Research Angiogenesis and VEGF in Cancer with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Angiogenesis and VEGF in Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers